Purpose: The aim of this study was to investigate the usability of MUC1 and p53 for differential diagnosis of noninvasive papillary urothelial neoplasias, especially for distinguishing papillary urothelial neoplasm of low malignant potential (PUNLMP) from low-grade papillary urothelial carcinoma (LGPUC) when the histologic signs are not obvious.
Materials And Methods: Seventeen biopsy specimens of the patients with PUNLMP, 20 with LGPUC and 13 with high-grade papillary urothelial carcinoma (HGPUC) were stained for MUC1 and p53 protein by immunohistochemical methods. Histological grading was performed according to an algorithm, which allows histological parameters used in 2004 WHO/ISUP 1998.
Results: We had obvious statistical difference for aberrant expression pattern of MUC1 between PUNLMP and LGPUC-HGPUC (P = 0.007). Positivity of MUC1 expression in cytoplasm of basal cells was more observed in HGPUC and LGPUC, whereas PUNLMP was more often showing apical and superficial positivity of MUC1 expression (P = 0.001 and 0.011). Nuclear p53 protein in HGPUC was obviously more frequent than that in LGPUC and PUNLMP (P < 0.001). Measures showed statistical difference among aberrant MUC1 expression, p53 overexpression, and tumor grade (P < 0.001).
Conclusions: MUC1 and p53 may be helpful immunohistochemical markers for distinguishing PUNLMP from LGPUC and HGPUC, when the histologic signs are not obvious.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4103/IJPM.IJPM_204_16 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cutaneous Metastasis of Bladder Cancer: A Systematic Review.
Cureus
November 2024
Department of Obstetrics and Gynecology, Beaumont Hospital, Dearborn, USA.
Bladder cancer is one of the main causes of urogenital cancer (30-35% of the total urological cancers). Although metastases from urologic tumors are rare, it is associated with a high mortality rate. The location and pattern of metastasis are random and unpredictable.
View Article and Find Full Text PDFUrothelial carcinoma in situ with "early papillary formation" vs "lateral spread/shoulder lesion" of prior high-grade noninvasive papillary urothelial carcinoma: A survey of pathologist and urologist interpretations.
Am J Clin Pathol
December 2024
Department of Pathology and Laboratory Medicine, Cleveland Clinic Foundation, Cleveland, OH, United States.
Objectives: Urothelial carcinoma in situ (CIS) with early papillary formation is terminology sometimes used to suggest incipient high-grade papillary urothelial carcinoma (PUC) but may lead to confusion between true CIS and lateral flat spread of PUC.
Methods: It remains unclear how pathologists and urologists interpret this scenario, so a survey was circulated to 68 pathologists (group 1 = 28 academic genitourinary pathologists; group 2 = 17 pathologists with a self-reported genitourinary focus; group 3 = 23 pathologists self-reported as not genitourinary specialists) and 32 urologists.
Results: Regarding atypical urothelial lesions that appear mainly flat but contain possible papillae, group 3 was more likely to label this as CIS compared with groups 1 and 2 (35% for group 3 vs 13% for groups 1 and 2), while groups 1 and 2 more often adopted another descriptive diagnosis, such as "CIS with early papillary features" (38% for groups 1 and 2 vs 13% for group 3).
Development and validation of a radiomics-based nomogram for predicting pathological grade of upper urinary tract urothelial carcinoma.
BMC Cancer
December 2024
Department of Urology, The 2nd Affiliated Hospital of Kunming Medical University, No. 374 Dianmian Road, Kunming, Yunnan, 650101, People's Republic of China.
Background: Upper urinary tract urothelial carcinoma (UTUC) is a rare and highly aggressive malignancy characterized by poor prognosis, making the accurate identification of high-grade (HG) UTUC essential for subsequent treatment strategies. This study aims to develop and validate a nomogram model using computed tomography urography (CTU) images to predict HG UTUC.
Methods: A retrospective cohort study was conducted to include patients with UTUC who underwent radical nephroureterectomy and received a CTU examination prior to surgery.
Prevalence and clinical significance of Claudin-3 expression in cancer: a tissue microarray study on 14,966 tumor samples.
Biomark Res
December 2024
Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, Hamburg, 20246, Germany.
Background: Claudin-3 (CLDN3) participates in the formation of the tight-junctions (TJs) that regulate intercellular permeability. Altered CLDN3 expression has been linked to tumor progression in multiple tumor types. Despite its widespread expression in normal epithelial cells, CLDN3 is considered an attractive drug target candidate, since it may be more accessible in cancer cells than in normal cells due to their less orchestrated cell growth.
View Article and Find Full Text PDFNectin-4 Positivity in Genitourinary Malignancies: A Systematic Review.
JCO Precis Oncol
December 2024
Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy.
Article Synopsis
- - The study investigates the expression of nectin-4 (N4) in various genitourinary (GU) cancers, particularly focusing on its relevance as a potential target for antibody-drug conjugates, given its aberrant expression in malignancies like urothelial carcinoma of the bladder (UBC).
- - A systematic review analyzed 25 studies on N4 positivity across different GU tumors, finding that N4 positivity is generally higher in bladder cancers, especially in metastatic and non-muscle-invasive stages, compared to other types like upper tract urothelial carcinoma and non-urothelial cancers.
- - The findings suggest that non-urothelial malignancies have lower rates of N4 positivity compared to bladder cancer,
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!